BioCentury
ARTICLE | Clinical News

AEOL 10150: Ph I started

February 24, 2017 2:20 AM UTC

Aeolus began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of subcutaneous AEOL 10150 in up to 12 healthy volunteers. The company is developing AEOL 10150 for the indicat...

BCIQ Company Profiles

Aeolus Pharmaceuticals Inc.